Gossamer Bio (NASDAQ:GOSS) Receives Overweight Rating from Piper Sandler

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “overweight” rating restated by analysts at Piper Sandler in a research note issued on Wednesday, Benzinga reports. They presently have a $15.00 price objective on the stock.

A number of other research firms have also recently weighed in on GOSS. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Wednesday, March 6th. The Goldman Sachs Group lowered their price objective on Gossamer Bio from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 6th. Finally, Wedbush restated an “outperform” rating and set a $6.00 price target on shares of Gossamer Bio in a research report on Wednesday, March 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Gossamer Bio has an average rating of “Moderate Buy” and a consensus target price of $8.05.

Gossamer Bio Trading Up 0.9 %

Shares of NASDAQ:GOSS opened at $1.18 on Wednesday. Gossamer Bio has a 12-month low of $0.45 and a 12-month high of $1.88. The business’s fifty day simple moving average is $1.14 and its 200-day simple moving average is $0.91. The company has a market capitalization of $266.18 million, a PE ratio of -0.85 and a beta of 1.73. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 3.14.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). As a group, equities research analysts predict that Gossamer Bio will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Gossamer Bio news, CEO Faheem Hasnain sold 23,172 shares of Gossamer Bio stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $1.16, for a total value of $26,879.52. Following the sale, the chief executive officer now owns 120,293 shares of the company’s stock, valued at approximately $139,539.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 33,620 shares of company stock valued at $39,682. 9.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Atom Investors LP acquired a new position in Gossamer Bio in the 4th quarter valued at $28,000. Bayesian Capital Management LP purchased a new stake in Gossamer Bio during the 2nd quarter worth $29,000. Dark Forest Capital Management LP acquired a new position in Gossamer Bio in the 1st quarter worth $30,000. Virtu Financial LLC acquired a new position in Gossamer Bio in the 4th quarter worth $30,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at about $31,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.